loader
Please Wait
Applying Filters...

Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Approved Drug Products containing 205718 listed in the FDA Orange Book. Original Data : FDA Website

    Client Virtual Booth
    Menu

    Helsinn Advanced Synthesis

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Send me more info on How To Grow My Business Digitally?

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 HELSINN HLTHCARE (1)

    filter

    01 CAPSULE;ORAL (1)

    filter

    01 RX (1)

    filter

    01 AKYNZEO (1)

    filter

    01 Yes (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us
    Contact Supplier
    • FDA
    • EDQM
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    NETUPITANT; PALONOSETRON HYDROCHLORIDE

    PDF Supplier PDF
    URL Supplier Web Content
    CAPSULE; ORAL
    300MG;EQ 0.5MG BAS...
    2014-10-10
    205718
    AKYNZEO
    RX
    Yes
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content

    Looking for FDA Orange Book APPLICATION 205718

    Looking for FDA Orange Book APPLICATION 205718 1

    19

    Helsinn Advanced Synthesis, based in Switzerland, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.

    One of their notable products is NETUPITANT; PALONOSETRON HYDROCHLORIDE, with a corresponding application number 205718.

    Regulatory Information RX

    With a dosage strength 300MG;EQ 0.5MG BASE

    Dosage Form Route CAPSULE; ORAL

    Reference Listed Drug Yes

    Approved since 2014-10-10

    Post Enquiry
    POST ENQUIRY